Seroatlas · Human Serome Atlas

MAP1A

Microtubule-associated protein 1A

Also known as: MAP1A_HUMAN, MAP1L

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P78559
Gene
MAP1A
Ensembl
ENSG00000166963
Chromosome
15
Canonical length
2803 aa
Protein class
FDA approved drug targets, Plasma proteins, Predicted intracellular proteins
Subcellular location
Cytosol,Mid piece,Principal piece

OverviewNCBI Gene

This gene encodes a protein that belongs to the microtubule-associated protein family. The proteins of this family are thought to be involved in microtubule assembly, which is an essential step in neurogenesis. The product of this gene is a precursor polypeptide that presumably undergoes proteolytic processing to generate the final MAP1A heavy chain and LC2 light chain. Expression of this gene is almost exclusively in the brain. Studies of the rat microtubule-associated protein 1A gene suggested a role in early events of spinal cord development. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

2803 residues, UniProt reviewed canonical sequence.

>P78559|MAP1A
     1  MDGVAEFSEY VSETVDVPSP FDLLEPPTSG GFLKLSKPCC YIFPGGRGDS ALFAVNGFNI
    61  LVDGGSDRKS CFWKLVRHLD RIDSVLLTHI GADNLPGING LLQRKVAELE EEQSQGSSSY
   121  SDWVKNLISP ELGVVFFNVP EKLRLPDASR KAKRSIEEAC LTLQHLNRLG IQAEPLYRVV
   181  SNTIEPLTLF HKMGVGRLDM YVLNPVKDSK EMQFLMQKWA GNSKAKTGIV LPNGKEAEIS
   241  VPYLTSITAL VVWLPANPTE KIVRVLFPGN APQNKILEGL EKLRHLDFLR YPVATQKDLA
   301  SGAVPTNLKP SKIKQRADSK ESLKATTKTA VSKLAKREEV VEEGAKEARS ELAKELAKTE
   361  KKAKESSEKP PEKPAKPERV KTESSEALKA EKRKLIKDKV GKKHLKEKIS KLEEKKDKEK
   421  KEIKKERKEL KKDEGRKEEK KDAKKEEKRK DTKPELKKIS KPDLKPFTPE VRKTLYKAKV
   481  PGRVKIDRSR AIRGEKELSS EPQTPPAQKG TVPLPTISGH RELVLSSPED LTQDFEEMKR
   541  EERALLAEQR DTGLGDKPFP LDTAEEGPPS TAIQGTPPSV PGLGQEEHVM KEKELVPEVP
   601  EEQGSKDRGL DSGAETEEEK DTWEEKKQRE AERLPDRTEA REESEPEVKE DVIEKAELEE
   661  MEEVHPSDEE EEDATKAEGF YQKHMQEPLK VTPRSREAFG GRELGLQGKA PEKETSLFLS
   721  SLTTPAGATE HVSYIQDETI PGYSETEQTI SDEEIHDEPE ERPAPPRFHT STYDLPGPEG
   781  AGPFEASQPA DSAVPATSGK VYGTPETELT YPTNIVAAPL AEEEHVSSAT SITECDKLSS
   841  FATSVAEDQS VASLTAPQTE ETGKSSLLLD TVTSIPSSRT EATQGLDYVP SAGTISPTSS
   901  LEEDKGFKSP PCEDFSVTGE SEKRGEIIGK GLSGERAVEE EEEETANVEM SEKLCSQYGT
   961  PVFSAPGHAL HPGEPALGEA EERCLSPDDS TVKMASPPPS GPPSATHTPF HQSPVEEKSE
  1021  PQDFQEADSW GDTKRTPGVG KEDAAEETVK PGPEEGTLEK EEKVPPPRSP QAQEAPVNID
  1081  EGLTGCTIQL LPAQDKAIVF EIMEAGEPTG PILGAEALPG GLRTLPQEPG KPQKDEVLRY
  1141  PDRSLSPEDA ESLSVLSVPS PDTANQEPTP KSPCGLTEQY LHKDRWPEVS PEDTQSLSLS
  1201  EESPSKETSL DVSSKQLSPE SLGTLQFGEL NLGKEEMGHL MQAEDTSHHT APMSVPEPHA
  1261  ATASPPTDGT TRYSAQTDIT DDSLDRKSPA SSFSHSTPSG NGKYLPGAIT SPDEHILTPD
  1321  SSFSKSPESL PGPALEDIAI KWEDKVPGLK DRTSEQKKEP EPKDEVLQQK DKTLEHKEVV
  1381  EPKDTAIYQK DEALHVKNEA VKQQDKALEQ KGRDLEQKDT ALEQKDKALE PKDKDLEEKD
  1441  KALEQKDKIP EEKDKALEQK DTALEQKDKA LEPKDKDLEQ KDRVLEQKEK IPEEKDKALD
  1501  QKVRSVEHKA PEDTVAEMKD RDLEQTDKAP EQKHQAQEQK DKVSEKKDQA LEQKYWALGQ
  1561  KDEALEQNIQ ALEENHQTQE QESLVQEDKT RKPKMLEEKS PEKVKAMEEK LEALLEKTKA
  1621  LGLEESLVQE GRAREQEEKY WRGQDVVQEW QETSPTREEP AGEQKELAPA WEDTSPEQDN
  1681  RYWRGREDVA LEQDTYWREL SCERKVWFPH ELDGQGARPH YTEERESTFL DEGPDDEQEV
  1741  PLREHATRSP WASDFKDFQE SSPQKGLEVE RWLAESPVGL PPEEEDKLTR SPFEIISPPA
  1801  SPPEMVGQRV PSAPGQESPI PDPKLMPHMK NEPTTPSWLA DIPPWVPKDR PLPPAPLSPA
  1861  PGPPTPAPES HTPAPFSWGT AEYDSVVAAV QEGAAELEGG PYSPLGKDYR KAEGEREEEG
  1921  RAEAPDKSSH SSKVPEASKS HATTEPEQTE PEQREPTPYP DERSFQYADI YEQMMLTGLG
  1981  PACPTREPPL GAAGDWPPCL STKEAAAGRN TSAEKELSSP ISPKSLQSDT PTFSYAALAG
  2041  PTVPPRPEPG PSMEPSLTPP AVPPRAPILS KGPSPPLNGN ILSCSPDRRS PSPKESGRSH
  2101  WDDSTSDSEL EKGAREQPEK EAQSPSPPHP IPMGSPTLWP ETEAHVSPPL DSHLGPARPS
  2161  LDFPASAFGF SSLQPAPPQL PSPAEPRSAP CGSLAFSGDR ALALAPGPPT RTRHDEYLEV
  2221  TKAPSLDSSL PQLPSPSSPG APLLSNLPRP ASPALSEGSS SEATTPVISS VAERFSPSLE
  2281  AAEQESGELD PGMEPAAHSL WDLTPLSPAP PASLDLALAP APSLPGDMGD GILPCHLECS
  2341  EAATEKPSPF QVPSEDCAAN GPTETSPNPP GPAPAKAENE EAAACPAWER GAWPEGAERS
  2401  SRPDTLLSPE QPVCPAGGSG GPPSSASPEV EAGPQGCATE PRPHRGELSP SFLNPPLPPS
  2461  IDDRDLSTEE VRLVGRGGRR RVGGPGTTGG PCPVTDETPP TSASDSGSSQ SDSDVPPETE
  2521  ECPSITAEAA LDSDEDGDFL PVDKAGGVSG THHPRPGHDP PPLPQPDPRP SPPRPDVCMA
  2581  DPEGLSSESG RVERLREKEK VQGRVGRRAP GKAKPASPAR RLDLRGKRSP TPGKGPADRA
  2641  SRAPPRPRST TSQVTPAEEK DGHSPMSKGL VNGLKAGPMA LSSKGSSGAP VYVDLAYIPN
  2701  HCSGKTADLD FFRRVRASYY VVSGNDPANG EPSRAVLDAL LEGKAQWGEN LQVTLIPTHD
  2761  TEVTREWYQQ THEQQQQLNV LVLASSSTVV MQDESFPACK IEF

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against MAP1A can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0
Highest tissue expression
150 nTPM

Expression across tissuesHPA

Tissue

  • cerebral cortex: 150 nTPM
  • amygdala: 112 nTPM
  • hippocampal formation: 107 nTPM
  • midbrain: 81 nTPM
  • basal ganglia: 75 nTPM
  • hypothalamus: 74 nTPM

Single-cell type

  • platelets: 330 nCPM
  • respiratory ciliated cells: 181 nCPM
  • pdcs: 158 nCPM
  • corticotrophs: 137 nCPM
  • retinal horizontal cells: 124 nCPM
  • fallopian tube ciliated cells: 99 nCPM

Immune cell

  • plasmacytoid DC: 11 nTPM
  • T-reg: 0.1 nTPM
  • total PBMC: 0.1 nTPM
  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM

Brain region

  • cerebral cortex: 972 nTPM
  • pons: 728 nTPM
  • white matter: 619 nTPM
  • medulla oblongata: 539 nTPM
  • hippocampal formation: 505 nTPM
  • thalamus: 489 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about MAP1A.

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 428 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.19
gnomAD pLI
1
gnomAD missense Z
2.01
DepMap mean gene effect
-0.06
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of MAP1A in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads MAP1A as an antibody target. Whether an autoantibody or antibody against MAP1A could matter depends on whether native MAP1A is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

MAP1A is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label MAP1A as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/MAP1A. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...